RPG Life Sciences Ltd(RPGLIFE)

NSE: RPGLIFEBSE: 532983

₹ 2,605.05-0.50%refreshed 26 Oct, 11:30 am ISTMarket cap: ₹ 4,309 crNext results: 29 Oct 2026Website: www.rpglifesciences.comUpdated: 24 Oct 2026

About

RPG Life Sciences Ltd is an integrated Indian pharmaceutical company. It makes branded formulations, global generics and synthetic APIs for domestic and international markets. Revenue from operations was ₹707.52 cr in FY26, and exports made up 30.7% of total turnover. The company ranked 50 in the Indian Pharmaceutical Market (IPM) in June'26, up from 62 in Mar'25.^[1][2][3]

Business segments

Domestic Formulations: 68.3% of sales in Q1 FY27 at ₹132.5 cr (+14.8% YoY vs ₹115.4 cr). Sells in India and Nepal across the Mass, Mass Specialty and Specialty segments.^[3][2]
International Formulations: 18.0% of sales in Q1 FY27 at ₹35.0 cr (+7.7% YoY vs ₹32.5 cr). FY26 sales were ₹123.43 crores, down 6.7% because of inventory norms rationalisation.^[3][2]
API: 13.7% of sales in Q1 FY27 at ₹26.6 cr (+35.6% YoY vs ₹19.6 cr). FY26 API sales were ₹95.06 crores.^[3][2]
Revenue by geography in FY26: India ₹48,340 lakh (vs ₹42,241 lakh in FY25) and outside India ₹22,412 lakh (vs ₹23,102 lakh). Pharmaceuticals is the single reportable segment.^[2]

Brands and products

Flagship brand Naprosyn grew 15.6% in FY26 and is moving towards becoming the company's first ₹100 crores brand.^[2]
Branded generics include Azoran, Mofetyl and Arpimune (nephrology/immunosuppressants), Siloxogene and Tricaine MPS (gastrointestinal), and Dipsope, Diasafe, Losatec and Serformin (cardio-metabolic). The company has 6 textbook brands.^[2]
The company describes itself as a leader in immunosuppressant therapy. It aims to grow the immunosuppressant portfolio to ₹200+ cr, and tacrolimus IR and ER filings for regulated markets are in the pipeline.^[2][3][4]
Key APIs include Quinfamide, Azathioprine, Haloperidol, Risperidone, Propantheline Bromide and Lercanidipine.^[2]
Norpace (disopyramide) grew 62% in H1FY26. The company is the sole player in this molecule, whose current market is about ₹42 cr.^[5]
The MABs (monoclonal antibodies) portfolio grew 21% in H1FY26.^[5]

Manufacturing, approvals and R&D

Plants are at Ankleshwar and Navi Mumbai. About ₹140 cr of modernisation capex has gone in since FY22.^[6]
The Navi Mumbai API facility has three units: MF2 is dedicated to immunosuppressants, and MF3 and MF4 are multipurpose. It holds WHO GMP, TGA Australia and PMDA Japan GMP certifications.^[2]
Ankleshwar F2 holds WHO GMP, EU GMP (Hamburg), TGA Australia and Thai FDA GMP clearances and a Health Canada licence, plus Kenya, Ethiopia, Nigeria and Sudan certifications.^[2]
The MF4 API block was damaged by a fire that cost about ₹16 cr of H1FY26 sales. The FY26 annual report says the API plant is now fully operational.^[5][2]
R&D covers APIs and formulations, including modified release and complex generics, and there is a GLP analytical laboratory. FY26 approvals included Health Canada ANDS approval for Naproxen 220 mg and product approvals in UAE, Bolivia and Guatemala.^[2]
A cost-reduction project for an anti-psychotic API is expected to save about ₹1.5 crores a year from FY27.^[2]

Key operating numbers

IPM rank improved to 50 in June'26 from 62 in Mar'25. The company was among the top 5 fastest-growing companies in IPM in Q1 FY27.^[3]
Domestic Formulations grew 13.7% in FY26, against 8.6% for the IPM. In Q4 FY26 the company was the 4th fastest-growing among the Top 50 pharma companies.^[2]
Sales force productivity was ₹6.5 lakhs per representative per month in FY26, up from ₹5.7 lakhs the year before. It was above ₹6.5 lakh in Q1 FY27.^[2][3]

Customers and distribution

Domestic customers are distributors and wholesalers. International and API customers are pharmaceutical companies, including Big Pharma and leading generic firms.^[2]
Exports were 30.7% of total turnover in FY26. The company serves over 63 countries across six continents, with markets including the UK, Australia, Canada, Myanmar and Germany.^[2]
In India the company sells in 28 states and 4 union territories. Its RPGServ platform engages over 1,00,000 doctors, including more than 36,000 specialists.^[2]
International Formulations is targeting emerging markets including Myanmar, Vietnam, Philippines, Thailand, Sri Lanka, Egypt, Sudan and South Africa.^[7][5]

Expansion and API restructuring

The API business was moved into subsidiary RPG Active Pharma (RPGAP) through a slump sale. InvAscent is taking a 40% diluted stake through a primary issuance of about ₹243.33 Cr.^[3]
RPGAP is acquiring Raghava Life Sciences through a slump sale for about ₹135 cr including NWC. The Raghava plant's revenue potential is about ₹200 cr at full utilisation.^[3]
An ICICI term loan of 3,000 (2,000 drawn) was sanctioned for capex at the API factory. It is repayable in 12 quarterly instalments at 7.85%.^[2]
The company plans to modernise and expand both its formulations and API plants for exports.^[2]

Recent developments

RPG Active Pharma Limited was incorporated on 24 Dec 2025 as a wholly owned subsidiary to make and market APIs. It had not started operations in FY26.^[2]
On 24 September 2026, RPG Active Pharma completed the acquisition of Actis Generics Private Limited (deal value about ₹80 cr including NWC), which became a wholly owned subsidiary.^[8][3]
On 25 September 2026, RPG Active Pharma's board approved a scheme to amalgamate Actis Generics into itself. Actis has a net worth of ₹34.60 cr and revenue from operations of ₹45.96 cr.^[9]
A final dividend of Rs 24 per share was recommended for FY26.^[2]

Market Cap

₹4,309 Cr

High / Low

₹3,131 / 1,731

Stock P/E

52.7

Price / Book

7.2

Book Value

₹366

EPS

₹69.6

No. of Shares

1.65 Cr

ROCE

24.0%

ROE

19.0%

OPM

20.6%

Debt / Equity

0.03

Sales

₹708 Cr

Net Profit

₹115 Cr

Promoter holding

73.0%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials